Maxona Pharmaceuticals is developing MAX-001, a novel non-opioid, non-NSAID analgesic that utilizes a triple neurotransmitter mechanism to provide potent pain relief. This therapeutic aims to meet the significant demand for effective pain management solutions while mitigating the risks associated with opioid use and NSAID-related side effects.
Funding
$11.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The U.S. faces a significant need for safe and effective pain management solutions due to the opioid abuse epidemic and the limitations of NSAIDs. Current pain relief options often carry risks of addiction or adverse side effects, leaving many patients without adequate relief.
Solution
Maxona Pharmaceuticals is developing MAX-001, a novel non-opioid, non-NSAID analgesic intended to provide potent pain relief through a triple neurotransmitter mechanism. MAX-001 aims to address the unmet need for a safe and efficacious alternative to opioids and NSAIDs in treating both acute and chronic pain. The therapeutic is designed to deliver opioid-level efficacy without the associated clinical and societal side effects. Maxona is pursuing MAX-001 as a New Molecular Entity for pain management in the United States.
Target Audience
The primary target audience includes individuals suffering from acute and chronic pain, as well as healthcare providers seeking safer and more effective alternatives to opioid and NSAID analgesics.
Features
- Triple neurotransmitter mechanism of action for potent analgesic effect
- Non-opioid and non-NSAID formulation to minimize risks of addiction and adverse side effects
- Demonstrated analgesic effect in multiple in-vivo models
- Intended for the treatment of both acute and chronic pain
- Patent protection expected until September 2037